Skye Bioscience to Present at GLP-1-Based Therapeutics Summit: Maximizing Efficacy, Minimizing Risk with Peripheral CB1 Antagonism

AC Immune has amended its Morphomer Tau license and collaboration agreement with Lilly to develop Tau aggregation inhibitor small molecules for Alzheimer's disease and other neurodegenerative diseases. The agreement reflects significant progress made with Morphomer small molecules and includes an upfront payment, milestones, and potential royalties. IND-enabling studies are set to commence in H1 2026.